{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "35373274",
  "DateCompleted": {
    "Year": "2022",
    "Month": "04",
    "Day": "05"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "06",
    "Day": "08"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1158/2159-8290.CD-NB2022-0016"
    ],
    "Journal": {
      "ISSN": "2159-8290",
      "JournalIssue": {
        "Volume": "12",
        "Issue": "4",
        "PubDate": {
          "Year": "2022",
          "Month": "Apr",
          "Day": "01"
        }
      },
      "Title": "Cancer discovery",
      "ISOAbbreviation": "Cancer Discov"
    },
    "ArticleTitle": "Rare Ovarian Cancer's First Positive Trial.",
    "Pagination": {
      "StartPage": "879",
      "MedlinePgn": "879"
    },
    "Abstract": {
      "AbstractText": [
        "The MEK1/2 inhibitor trametinib increases progression-free survival from 7.2 months to 13 months in women with recurrent low-grade serous ovarian cancer. The drug also boosts the overall response rate from 6% to 26%."
      ],
      "CopyrightInformation": "\u00a92022 American Association for Cancer Research."
    },
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Cancer Discov",
    "NlmUniqueID": "101561693",
    "ISSNLinking": "2159-8274"
  },
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Cystadenocarcinoma, Serous"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Ovarian Neoplasms"
    }
  ]
}